title: Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
abstract: OBJECTIVE
  To compare continued indinavir (IDV) 8-hourly (q8h) with switching to indinavir/ritonavir (IDV/RTV) 12-hourly (q12h) in HIV-positive patients having suppressed viral load with IDV q8h plus two nucleoside reverse transcriptase inhibitors (NRTI).
  
  
  METHODS
  Multicentre, international, randomized, open-label study enrolling HIV-1 infected patients on IDV 800 mg q8h plus two NRTI with CD4 cell counts > or = 100 x 106/l and plasma HIV RNA < 500 copies/ml for > or = 3 months.
  
  
  METHODS
  Patients were randomized to continue on the same regimen or to switch to IDV plus liquid RTV (IDV/RTV 800 mg/100 mg q12h). Primary endpoint was the proportion of patients remaining < 500 copies/ml at 48 weeks.
  
  
  RESULTS
  A total of 323 patients (IDV/RTV, 162; IDV, 161) were evaluable. At 48 weeks, the proportions of patients with plasma HIV RNA < 500 copies/ml were 93%, 88% and 58% in the IDV/RTV arm versus 92% (P = 1), 86% (P = 0.87) and 74% (P = 0.003) in the IDV arm using on-treatment (OT) and intent-to-treat (ITT) [switches included (ITT, S = I) and switches = failure (ITT, S = F)] analyses respectively. Mean increase in CD4 cell count was 88 x 106/cells/l (IDV/RTV arm) and 60 x 106 cells/l (IDV arm) (P = 0.08). More patients discontinued study medication due to adverse events in the IDV/RTV arm than in the IDV arm (P < 0.001).
  
  
  CONCLUSIONS
  Equivalence of continuing IDV q8h versus switching to IDV/RTV (liquid) q12h in suppressed stable patients was demonstrated by OT and ITT S = I analyses. However, the IDV q8h arm performed better when discontinuations were classified as failures. IDV/RTV q12h can be convenient and equally effective for patients able to tolerate it.
authors.affiliation: Hospital Clinic-IDIBAPS, University of Barcelona, Spain.
authors.forename: Juan A
authors.initials: JA
authors.lastname: Arnaiz
authors.forename: Josep
authors.initials: J
authors.lastname: Mallolas
authors.forename: Daniel
authors.initials: D
authors.lastname: Podzamczer
authors.forename: Jan
authors.initials: J
authors.lastname: Gerstoft
authors.forename: Jens D
authors.initials: JD
authors.lastname: Lundgren
authors.forename: Pedro
authors.initials: P
authors.lastname: Cahn
authors.forename: Gerd
authors.initials: G
authors.lastname: Fätkenheuer
authors.forename: Antonella
authors.initials: A
authors.lastname: D'Arminio-Monforte
authors.forename: Arnaldo
authors.initials: A
authors.lastname: Casiró
authors.forename: Peter
authors.initials: P
authors.lastname: Reiss
authors.forename: David M
authors.initials: DM
authors.lastname: Burger
authors.forename: Michael
authors.initials: M
authors.lastname: Stek
authors.forename: José M
authors.initials: JM
authors.lastname: Gatell
mesh_terms: D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D019469:Indinavir / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D019469:Indinavir; D019438:Ritonavir